|
news.Interferon-beta therapy does not appear to reduce disability progression in adults with relapsing-remitting multiple sclerosis, according to a retrospective study inUsing Canadian databases, researchers studied some 2700 adults who were eligible for interferon-beta therapy: about a third received therapy, a third served as contemporary untreated controls, and another third served as historical...
|
